Navigation Links
Uptake Medical® Expands Executive Team, Announces European General Manager Lloyd Mencinger
Date:9/6/2011

TUSTIN, Calif., Sept. 6, 2011 /PRNewswire/ -- Uptake Medical® Corp., maker of InterVapor™, a minimally invasive treatment for severe emphysema, today announced that seasoned medical device executive Lloyd Mencinger has joined the company as European General Manager, effective September 1, 2011.

Mr. Mencinger joins Uptake Medical with nearly three decades of broad functional experience with medical device leaders such as Boston Scientific, Baxter, and American Hospital Supply and most recently with Tenent Healthcare serving as Senior Vice President of Business Development, providing him with insights into the evolving healthcare environment. His tenure with Boston Scientific included nearly 10 years living within the European Union focusing on sales, marketing, business development, operations and clinical economics & government affairs.

"It is rare to find such broad functional expertise in one individual. We are thrilled to welcome Lloyd to Uptake Medical," said King Nelson, President and CEO. "Specifically, Lloyd's extensive experience in building markets for innovative technologies, his understanding of global healthcare environments and his ability to navigate appropriate channels to secure reimbursement will be major assets as we move towards commercialization."

InterVapor is the first and only personalized endoscopic lung volume reduction procedure to use the energy of heated water vapor and the body's own healing process to target hyperinflation. With InterVapor, the diseased lung volume is reduced, giving patients with severe emphysema clinically meaningful improvement in breathing function and quality of life. This is done without implants or chemicals being placed or left behind in the delicate lung tissue.

About his appointment, Mr. Mencinger commented, "The global burden of emphysema is large and growing, and the opportunity to introduce a unique technology, such as InterVapor, to help this population of patients is truly exciting. Uptake Medical's pioneering approach to lung volume reduction is certain to help improve the quality of life for many emphysema sufferers."

About Emphysema:

Emphysema and chronic bronchitis are captured under the umbrella of Chronic Obstructive Pulmonary Disease (COPD). The Word Health Organization has stated that the incidence of COPD is on the rise, on pace to becoming the third leading cause of death by 2030. In the United States, where nearly 5 million people are diagnosed with emphysema, it already holds this position, with one person dying every 4 minutes. Debilitating and costly, nearly $50 billion was spent on the direct and indirect costs associated with COPD in the U.S. in 2010.

About Uptake Medical:

With headquarters in Tustin, Calif., Uptake Medical develops innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor, is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body's natural healing process without leaving any foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life. More information can be found at www.uptakemedical.com.

Uptake Medical and InterVapor are registered trademarks and trademarks of Uptake Medical.


'/>"/>
SOURCE Uptake Medical Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market
2. Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions
3. Uptake Medical Announces Scott Huennekens Elected to Board of Directors
4. The Harley Medical Group Sees an Uptake in Surgery Bookings for Christmas
5. Uptake Medical Names J.C. MacRae as Chief Financial Officer
6. Driven by the Uptake of Several Emerging Agents, the MRSA Drug Market Will Increase From $631 Million in 2009 to $752 Million in 2019
7. Introduction of New Products and Increased Uptake of Innovative Materials to Drive US Bone Graft Substitute Market to Nearly $2.3 Billion by 2015
8. The Continued Uptake of Key Agents Such as Januvia, Bydureon and Byetta Will Drive The Type 2 Diabetes Drug Market to Nearly Double From $19 Billion in 2009 to $36 Billion in 2019
9. BridgePoint Medical®, Inc. Completes and Submits to FDA in the U.S. FAST-CTOs With the CrossBoss® and Stingray® CTO Recanalization System
10. Pacira Pharmaceuticals, Inc. Expands EXPAREL™ Commercial Team Infrastructure
11. IRIDEX Expands ENT Laser Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Report Details ... Alzheimer,s Disease Therapeutics and ... our new study reveals trends, R&D progress, and predicted ... the Alzheimer,s disease therapeutics and diagnostics market. Our new ... - How is the Alzheimer,s disease therapeutics and diagnostics ...
(Date:1/19/2017)... BOSTON , Jan. 19, 2017  Stealth BioTherapeutics ... therapeutics to treat mitochondrial dysfunction, today announced new additions ... , M.D., as Chief Medical Officer, and Daniel ... Stealth announced that Jim Carr , Pharm.D. has ... "We are pleased to welcome Doug and Daniel ...
(Date:1/19/2017)... 19, 2017 Accuray Incorporated (Nasdaq: ... Systems continue to set the bar for excellence in ... overall user satisfaction rating among radiation treatment delivery systems ... Buyline Market Intelligence Briefing™. The most recent ratings trend ... among industry peers for 11 of the past 12 ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... ... “Mary Magdalene: Grace is Greater than Sin”: a unique and memorable piece ... “Mary Magdalene: Grace is Greater than Sin” is the creation of published author, Brenda ... women who had little knowledge of the female characters portrayed in the Holy Bible. ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “Christmas in Suffolk”: ... of published author, Sara Seymour, who lives in Lafayette, Indiana where she works in ... on iced coffees and writes. , Published by Christian Faith Publishing, Sara Seymour’s new ...
(Date:1/19/2017)... ... January 20, 2017 , ... Today, the Centers for Medicare ... four of CMS’s Alternative Payment Models (APMs) in 2017. Clinicians who participate in APMs ... are an important part of the Administration’s effort to build a system that delivers ...
(Date:1/19/2017)... ... January 19, 2017 , ... This month, the CEO and Clinical ... of their drug rehab center in Delray Beach, Florida has been changed from Sober ... stars such as Philip Seymour Hoffman and Chris Farley are dying from heroin overdoses, ...
(Date:1/19/2017)... ... 19, 2017 , ... WholeHealth is announcing their participation in ... Andrew Petersen and Trish Henrie-Barrus will be present Saturday and Sunday in the ... , “We know it’s easy to get carried away when you’re having ...
Breaking Medicine News(10 mins):